<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252404</url>
  </required_header>
  <id_info>
    <org_study_id>Arcothova</org_study_id>
    <nct_id>NCT04252404</nct_id>
  </id_info>
  <brief_title>FranceLEVO - Zimino Registry (FZR)</brief_title>
  <acronym>FZR</acronym>
  <official_title>FranceLEVO - Zimino® Registry: a French Registry Evaluating the Use of Levosimendan (Zimino®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcothova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcothova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French National Authority for Health (Haute Autorité de santé) requested a registry study
      to obtain post-market surveillance data to describe baseline clinical profiles, management
      and outcome of patients treated with Zimino®. This study is designed to provide real-life
      data on the use, safety and clinical outcomes of Zimino® in routine clinical practice in
      France.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a real-life, non-interventional, observational, multicentre study in all patients
      (including children) receiving Zimino® in France.

      The patients will be evaluated during the index hospitalisation and on follow-up days 30
      (±15) and 90 (±15) after hospital discharge. The follow-up can be a phone call or a visit to
      the hospital. Patients who meet the eligibility criteria will be identified consecutively at
      each hospital. The participating hospitals will vary in size and medical activities,
      depending on their location and the population size they serve.

      The physician will determine the patient's treatment strategy. Drug prescriptions and the
      indications to perform diagnostic or therapeutic procedures will be left completely to the
      discretion of the physicians.

      The estimated enrollment period is 12 months (enrollment of the first patient - enrollment of
      the last patient), or less if the cohort (n=600) is completed earlier, and the maximum total
      data collection period is 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 28, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indication for levosimendan (Zimino)</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Physicians will be requested to choose one of the following indications (pop-up list):
Cardiogenic shock (medical setting or post cardiac surgery)
Heart failure decompensation (medical, setting)
Low cardiac output syndrome (post cardiac surgery)
Heart failure decompensation in a patient receiving beta-blockers
ECMO weaning
Repetitive use in a patient with end-stage heart failure
Other (text)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose of levosimendan (Zimino) (in µg/kg/min)</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Physicians will be requested to describe the levosimendan regimen used:
A) Loading dose (in µg/kg) B) Dose of the continuous infusion (in µg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of levosimendan (Zimino) infusion</measure>
    <time_frame>from January 28, 2020 until January 28, 2021</time_frame>
    <description>Number of hours during which the patient received levosimendan</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiac dysfunction receiving levosimendan (Zimino®)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving Zimino® treatment

          -  Patients or patient's families not objecting to the patient's participation in the
             study.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CHOLLEY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arcothova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe MAURIAT, MD</last_name>
    <phone>0688522020</phone>
    <email>philippe.mauriat@me.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcothova</investigator_affiliation>
    <investigator_full_name>Cholley Bernard</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>low cardiac output syndrome</keyword>
  <keyword>cardiogenic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will remain with the sponsor (Arcothova)</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04252404/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04252404/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

